Clinical Research Network: JHCRN Infrastructure and Lessons Learned.

Clinical research studies are becoming increasingly complex resulting in compounded work burden and longer study cycle times, each fueling runaway costs. The impact of protocol complexity often results in inadequate recruitment and insufficient sample sizes, which challenges validity and generalizability. Understanding the need to provide an alternative model to engage researchers and sponsors and bringing clinical research opportunities to the broader community, clinical research networks (CRN) have been proposed and initiated in the United States and other parts of the world.

Harnessing nature's therapeutic potential: A review of natural products in prostate cancer management.

Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer-related death among men in the United States. The global burden of this disease is rising, placing significant strain on healthcare systems worldwide. Although definitive therapies like surgery and radiation are often effective, prostate cancer can recur and progress to castration-resistant prostate cancer in some cases.

Navigating the unseen peril: safeguarding medical imaging in the age of AI.

In response to the increasing significance of artificial intelligence (AI) in healthcare, there has been increased attention - including a Presidential executive order to create an AI Safety Institute - to the potential threats posed by AI. While much attention has been given to the conventional risks AI poses to cybersecurity, and critical infrastructure, here we provide an overview of some unique challenges of AI for the medical community. Above and beyond obvious concerns about vetting algorithms that impact patient care, there are additional subtle yet equally important things to consider: the potential harm AI poses to its own integrity and the broader medical information ecosystem.

Association of SGLT2 Inhibitor Initiation and PSA Response in Prostate Cancer.

Introduction: Non-castrating therapies are an unmet clinical need for patients with advanced prostate cancer. To maximize quality of life and prioritize cardiovascular health, we investigated SGLT2 inhibitors as a non-castrating therapy in patients with prostate cancer.

Materials And Methods: We conducted a retrospective analysis of patients with either local or biochemically recurrent prostate cancer who initiated therapy with an SGLT2 inhibitor without concurrent androgen deprivation therapy.